AI-generated summary
The authors report a pilot cohort study of transcranial photobiomodulation with a helmet device added to standard care for people in opioid addiction treatment in West Virginia, compared with standard care alone. They describe statistically significant reductions in opioid craving scores and improved depression symptoms in the treatment group, and suggest the approach could be promising, warranting larger randomized trials.
- Who or what was studied
- Individuals undergoing treatment for opioid addiction at a rehabilitation center in West Virginia
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The abstract describes a pilot quasi-experimental design with a non-randomized control group, and the authors themselves call for larger randomized controlled trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Energy density (fluence)
- 172.8J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Transcranial photobiomodulation, Depression, Photobiomodulation therapy, Control group, Irradiance, Wavelength, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.